Skip to main content

James Crowe Archives

Twelve at Vanderbilt are among world’s highly cited researchers

Nov. 15, 2023—Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers.

Read more


Crowe, Osheroff honored by AAMC

Oct. 30, 2023—Vanderbilt's James E. Crowe, Jr, MD, and Neil Osheroff, PhD, are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event.

Read more


Crowe, Harris, Young elected as new AIMBE fellows

Mar. 30, 2023—Vanderbilt's James Crowe Jr., MD, Paul Harris, PhD, and Jamey Young, PhD, have been elected to the 2023 College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE).

Read more


Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America

Oct. 6, 2022—Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.

Read more


Research probes cause of acute flaccid myelitis in children

Jun. 8, 2022—Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM).

Read more


Therapeutic antibodies for hantavirus

May. 24, 2021—Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential.

Read more


Novel way to neutralize Rift Valley Fever Virus

Apr. 1, 2021—The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

Read more


Exploiting viral vulnerabilities

Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

Read more


COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

Read more


Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

Read more


Research team isolates antibodies that may prevent rare polio-like illness in children linked to a respiratory infection

Jul. 3, 2020—Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

Read more


Antibodies eye Pacific Island “fever”

May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more